Related Experiment Video
Updated: Feb 14, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications
Erika Di Zazzo1, Giovanni Galasso1, Pia Giovannelli1
1Department of Biochemistry, Biophysics and General Pathology, University of Campania Luigi Vanvitelli, Naples, Italy.
Abstract:
A major challenge in clinical management of prostate cancer (PC) is to limit tumor growth and prevent metastatic spreading. Considerable efforts have been made to discover new compounds for PC therapy and recent years have seen promising progress in this field. Pharmacological approaches have been designed to achieve benefits in PC treatment and avoid the negative side effects resulting from administration of antagonists or agonists or new drugs. Nonetheless, the currently available therapies frequently induce resistance and PC progresses toward castration-resistant forms that can be caused by the androgen receptor reactivation and/or mutations, or derangement of signaling pathways. Preclinical and clinical findings have also shown that other nuclear receptors are frequently altered in PC. In this review, we focus on the role of estradiol/estradiol receptor (ER) axis, which controls PC growth and progression. Selective targeting of ER subtypes (α or β) may be an attractive way to limit the growth and spreading of prostatic cancer cells.
Insights
Targeting the estradiol/estradiol receptor (ER) axis offers a promising strategy to combat prostate cancer (PC) growth and metastasis. Selective ER subtype targeting may inhibit prostatic cancer cell proliferation and spread.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostate cancer (PC) management faces challenges in limiting tumor growth and preventing metastasis.
- Current therapies often lead to resistance and progression to castration-resistant forms.
- Alterations in nuclear receptors, including the estradiol/estradiol receptor (ER) axis, are frequently observed in PC.
Purpose of the Study:
- To review the role of the estradiol/estradiol receptor (ER) axis in prostate cancer (PC) growth and progression.
- To explore the potential of selectively targeting ER subtypes (α or β) for PC therapy.
Main Methods:
- Literature review of preclinical and clinical findings.
- Analysis of the impact of the estradiol/estradiol receptor (ER) axis on PC.
- Evaluation of selective ER subtype targeting strategies.
Main Results:
- The estradiol/estradiol receptor (ER) axis plays a significant role in controlling PC growth and progression.
- Selective targeting of ER subtypes (α or β) shows potential for PC treatment.
Conclusions:
- The estradiol/estradiol receptor (ER) axis is a critical factor in prostate cancer (PC) pathogenesis.
- Selective modulation of ER subtypes presents a viable therapeutic avenue to inhibit PC growth and metastasis.
Related Concept Videos
Internal Receptors
Therapeutic Index
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
G-protein Coupled Receptors
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...

